Compare JSPR & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JSPR | EDD |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4M | 345.5M |
| IPO Year | N/A | N/A |
| Metric | JSPR | EDD |
|---|---|---|
| Price | $1.81 | $5.51 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $25.60 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 254.3K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $4.22 |
| 52 Week High | $23.11 | $4.95 |
| Indicator | JSPR | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 53.91 |
| Support Level | $1.60 | $5.48 |
| Resistance Level | $1.93 | $5.69 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 36.90 | 51.35 |
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.